Breaking News, Trials & Filings

FDA Accepts Afrezza Submission

MannKind tries again with inhaled insulin

The FDA has acknowledged the resubmission of an NDA by MannKind Corp. for Afrezza (insulin human [rDNA origin]) Inhalation Powder. The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011 and assigned a user fee goal date of April 15, 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters